TY  - GEN
AU  - de Diego-Otero, Yolanda
AU  - Calvo-Medina, Rocio
AU  - Quintero-Navarro, Carolina
AU  - Sánchez-Salido, Lourdes
AU  - García-Guirado, Francisco
AU  - del Arco-Herrera, Ignacio
AU  - Fernández-Carvajal, Isabel
AU  - Ferrando-Lucas, Teresa
AU  - Caballero-Andaluz, Rafaela
AU  - Pérez-Costillas, Lucia
PY  - 2014
DO  - 10.1186/1745-6215-15-345
UR  - http://hdl.handle.net/20.500.12105/17075
AB  - BACKGROUND: Fragile X syndrome (FXS) is an inherited neurodevelopmental condition characterised by behavioural, learning disabilities, physical and neurological symptoms. In addition, an important degree of comorbidity with autism is also present....
LA  - eng
PB  - BioMed Central (BMC)
KW  - Antioxidants
KW  - Experimental treatment
KW  - Fragile X syndrome
KW  - Oxidative stress
KW  - Trial
KW  - Síndrome del cromosoma X frágil
KW  - Ácido ascórbico
KW  - Alfa-tocoferol
KW  - España
KW  - Resultado del tratamiento
KW  - Masculino
KW  - Adolescent Behavior
KW  - Adolescent Development
KW  - Antioxidants
KW  - Antioxidants
KW  - Biological Markers
KW  - Checklist
KW  - Child
KW  - Child Behavior
KW  - Child Development
KW  - Clinical Protocols
KW  - Cognition
KW  - Drug Combinations
KW  - Fragile X Syndrome
KW  - Humans
KW  - Male
KW  - Pilot Projects
KW  - Research Design
KW  - Spain
KW  - Time Factors
KW  - Treatment Outcome
KW  - Wechsler Scales
KW  - alpha-Tocopherol
KW  - Adolescent
TI  - A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial.
TY  - research article
ER  -